Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278)
Fast, easy summary view of NICE guidance on 'asthma'
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201)
NICE recommends omalizumab as possible additional treatment to standard asthma therapy for some people aged 6 years and over with severe persistent allergic asthma (see below).
Who can have omalizumab?
You (or your child) should be able to have omalizumab if you (or your child):
- have been diagnosed with a certain type of allergic asthma, and
- need continuous or frequent treatment with oral corticosteroids (at least 4 courses in the last year)
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended omalizumab because the benefit to patients justifies the cost.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: asthma
- None found
This page was last updated: 02 April 2014
- Web format
- Full Guidance (PDF)
- TA278 Omalizumab ar gyfer asthma alergaidd parhaus difrifol - Gwybodaeth i'r cyhoedd (fformat MS Word)
Information for the public
Implementation tools and resources
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.